UK markets closed
NIKKEI 225
26,871.27 +379.30 (+1.43%) HANG SENG
22,229.52 +510.46 (+2.35%) CRUDE OIL
109.74 +2.12 (+1.97%) GOLD FUTURES
1,823.40 -6.90 (-0.38%) DOW
31,438.26 -62.42 (-0.20%) BTC-GBP
17,071.06 -357.61 (-2.05%)
Abeona Therapeutics Inc. (0H7R.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 03:41PM BST
| Previous close | 0.1831 |
| Open | 0.1850 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.1850 - 0.1850 |
| 52-week range | 0.1850 - 0.1850 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 5.168M |
| Beta (5Y monthly) | 1.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8080 |
| Earnings date | 27 Jul 2022 - 01 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
- Zacks
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
- Zacks
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.
© 2022 Yahoo. All rights reserved.
